Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
These evidence-based guidelines are an updated version of those published in 2006. They have been produced after a literature review of the treatment and prophylaxis of methicillin-resistant Staphylococcus aureus (MRSA). The guidelines aim to complement those recently published for the antibiotic treatment of common and emerging community-onset MRSA infections in the UK. The guidelines have reviewed and updated, where appropriate, previous recommendations, taking into account any changes in the UK epidemiology of MRSA, ongoing national surveillance data and the value of new antistaphylococcal agents licensed for use in UK practice. Emerging therapies that have not been licensed for UK use are not reviewed, but their future potential role has been mentioned where deemed appropriate. Recommendations are given for the treatment of common infections caused by MRSA, elimination of MRSA from carriage sites and prophylaxis of surgical site infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984 · cited 1×
“The source of the vanA gene is obscure and some cases suggest transfer from other Gram-positive organisms,(49,50) but most isolates are resistant by non-transferable mechanisms.(51) Vancomycin-resistant MRSA have not been isolated in the UK and the HPA Reference Service has not confirmed any isolates with stable inter…”
BackgroundInfection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025025 · Cited by 1,095
Lodise, T. P., McKinnon, P. S., Swiderski, L., & Rybak, M. J. (2003) · Clinical Infectious Diseases · doi:10.1086/375057 · Cited by 604 · cited 1×
“We referred in previous guidance to two studies showing that a relatively short period of up to 48 h delay in switching from b-lactam antibiotics to appropriate therapy for non-severe methicillin-resistant infections does not affect outcome.(80,81) Previous guidance of a step-down approach to severe S.”
ResultInhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J. (2005) · The Journal of Infectious Diseases · doi:10.1086/430352 · Cited by 541 · cited 1×
“Of the new agents, daptomycin is inactivated by lung surfactant and therefore not recommended in the management of respiratory tract infection.(124) Recommendation 12: The treatment of infections in patients with bronchiectasis or chronic suppurative lung disease without pneumonia, where MRSA is deemed significant, is…”
BackgroundPractice Guidelines for Outpatient Parenteral Antimicrobial Therapy
Tice, A. D., Rehm, S. J., Dalovisio, J. R., Bradley, J. S., Martinelli, L. P., Graham, D. R., Gainer, R. B., Kunkel, M. J., Yancey, R. W., & Williams, D. N. (2004) · Clinical Infectious Diseases · doi:10.1086/420939 · Cited by 532
Toh, S., Xiong, L., Arias, C. A., Villegas, M. V., Lolans, K., Quinn, J., & Mankin, A. S. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05744.x · Cited by 338
Daptomycin in the Treatment of Patients with Infective Endocarditis: Experience from a Registry
Levine, D. P., & Lamp, K. C. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.07.011 · Cited by 105
Response to Emerging Infection Leading to Outbreak of Linezolid-Resistant Enterococci
Kainer, M. A., Devasia, R. A., Jones, T. F., Simmons, B. P., Melton, K., Chow, S., Broyles, J., Moore, K. L., Craig, A. S., & Schaffner, W. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1307.070019 · Cited by 96
Sander, A., Beiderlinden, M., Schmid, E., & Peters, J. (2002) · Intensive Care Medicine · doi:10.1007/s00134-002-1358-7 · Cited by 29
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Clinical practice guidelines for antimicrobial prophylaxis in surgery
Bratzler, D. W., Dellinger, E. P., Olsen, K. M., Perl, T. M., Auwaerter, P. G., Bolon, M. K., Fish, D. N., Napolitano, L. M., Sawyer, R. G., Slain, D., et al. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120568 · Cited by 2,591
David, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery
Bratzler, D. W., Dellinger, E. P., Olsen, K. M., Perl, T. M., Auwaerter, P. G., Bolon, M. K., Fish, D. N., Napolitano, L. M., Sawyer, R. G., Slain, D., et al. (2013) · Surgical Infections · doi:10.1089/sur.2013.9999 · Cited by 1,197
Spondylodiscitis: update on diagnosis and management
Gouliouris, T., Aliyu, S. H., & Brown, N. M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq303 · Cited by 780
Metadata
- Authors
- Gould, F. K., Brindle, R., Chadwick, P. R., Fraise, A. P., Hill, S., Nathwani, D., Ridgway, G. L., Spry, M. J., Warren, R. E., & on behalf of the MRSA Working Party of the British Society for Antimicrobial Chemotherapy
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-05
- Volume
- 63
- Issue
- 5
- Pages
- 849-861
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2099274786
- Cited by
- 155
- References
- 10
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.